BeyondSpring Shares Shares Jump Premarket Following Positive Trial Results

Dow Jones12-12

By Robb M. Stewart

BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment.

In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025.

BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone.

The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates.

Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia, while maintaining a favorable tolerability profile, BeyondSpring said.

"These data from nearly 500 Asian patients further strengthen the robust global evidence supporting Plinabulin's potential to become a new standard of care for EGFR wild-type NSCLC," Lan Huang, company co-founder, chairman and chief executive, said.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

December 12, 2025 07:38 ET (12:38 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590061895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590061895","market":"nz","top_or_hot":-1,"title":"BeyondSpring Shares Shares Jump Premarket Following Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment. \n</p>\n<p>\n  In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025. \n</p>\n<p>\n  BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone. \n</p>\n<p>\n  The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates. \n</p>\n<p>\n  Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia, while maintaining a favorable tolerability profile, BeyondSpring said. \n</p>\n<p>\n  \"These data from nearly 500 Asian patients further strengthen the robust global evidence supporting Plinabulin's potential to become a new standard of care for EGFR wild-type NSCLC,\" Lan Huang, company co-founder, chairman and chief executive, said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 07:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeyondSpring Shares Shares Jump Premarket Following Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyondSpring Shares Shares Jump Premarket Following Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-12 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment. \n</p>\n<p>\n  In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025. \n</p>\n<p>\n  BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone. \n</p>\n<p>\n  The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates. \n</p>\n<p>\n  Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia, while maintaining a favorable tolerability profile, BeyondSpring said. \n</p>\n<p>\n  \"These data from nearly 500 Asian patients further strengthen the robust global evidence supporting Plinabulin's potential to become a new standard of care for EGFR wild-type NSCLC,\" Lan Huang, company co-founder, chairman and chief executive, said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 07:38 ET (12:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590061895","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590061895","pubTimestamp":1765543080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment.In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025.BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone.The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates.Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in doce","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BYSI":"万春药业"},"translate_title":"BeyondSpring股价在积极的试验结果后盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BYSI":0.9},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment. \n\n\n  In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025. \n\n\n  BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone. \n\n\n  The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates. \n\n\n  Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in docetaxel-induced grade 4 neutropenia, while maintaining a favorable tolerability profile, BeyondSpring said. \n\n\n  \"These data from nearly 500 Asian patients further strengthen the robust global evidence supporting Plinabulin's potential to become a new standard of care for EGFR wild-type NSCLC,\" Lan Huang, company co-founder, chairman and chief executive, said. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 07:38 ET (12:38 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590061895","isCrawlerRequest":true}